stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy
Please see updated information from the FDA
You'll see stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy.
This is due to new evidence of a higher risk of miscarriage and birth defects in women taking mycophenolate to prevent transplant rejection.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote